Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-28
2007-08-28
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S047000, C514S263200, C536S027300, C536S027600, C536S027610, C544S277000
Reexamination Certificate
active
10722702
ABSTRACT:
Disclosed are novel compounds that are A3adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.
REFERENCES:
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6770634 (2004-08-01), Zablocki et al.
patent: 6855818 (2005-02-01), Zablocki et al.
patent: WO 00/78777 (2000-12-01), None
patent: WO 00/78778 (2000-12-01), None
patent: WO 00/78779 (2000-12-01), None
Klotz et al. Naunyn-Schmiedeberg's Arch Pharm (1999), 360, 103-108.
Klotz et al: “2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at Human A3 Adenosine Receptors”, Nauny-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE., vol. 360, No. 2, 1999, pp. 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,2.
Baraldi et al: “Novel N6-(Substituted-phenylcarbamoyl) Adenosine-5′-Uronamides as Potent Agonist for A2 Adenosine Receptors”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, No. 3, Feb. 1996, pp. 802-806, XP002913657, ISSN: 0022-2623, conclusions on p. 804, pp. 803, col. 2, paragraph 4.
Elzein Elfatih
Palle Venkata
Varkhedkar Vaibhav
Zablocki Jeff
Clarke Pauline Ann
CV Therapeutics Inc.
Hartrum J. Elin
Jiang Shaojia Anna
Khare Devesh
LandOfFree
Adenosine A 3 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenosine A 3 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine A 3 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3890083